Patents by Inventor Matthew John Meyer
Matthew John Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11833215Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: June 4, 2020Date of Patent: December 5, 2023Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Publication number: 20220008426Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.Type: ApplicationFiled: March 3, 2021Publication date: January 13, 2022Inventors: Giordano CAPONIGRO, Vesselina COOKE, Matthew John MEYER, Darrin STUART
-
Publication number: 20210121460Abstract: The present invention relates to a pharmaceutical combination comprising dabrafenib, trametinib and an Erk-inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.Type: ApplicationFiled: March 29, 2019Publication date: April 29, 2021Inventors: Matthew John Meyer, Youzhen Wang
-
Patent number: 10973829Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.Type: GrantFiled: September 18, 2017Date of Patent: April 13, 2021Assignee: NOVARTIS AGInventors: Giordano Caponigro, Vesselina Cooke, Matthew John Meyer, Darrin Stuart
-
Publication number: 20210040205Abstract: The present disclosure relates to anti-CD32b antibody molecules which selectively bind human CD32b. Also provided herein are compositions comprising anti-CD32b antibody molecules in combination with other compounds, and methods of using the combinations to treat subject with cancer.Type: ApplicationFiled: October 23, 2018Publication date: February 11, 2021Inventors: Sunyoung JANG, Haihui LU, Matthew John MEYER, Ryan MOLONY, Karrie WONG
-
Publication number: 20200405875Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: June 4, 2020Publication date: December 31, 2020Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 10786578Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: July 27, 2015Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Publication number: 20190358236Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.Type: ApplicationFiled: September 18, 2017Publication date: November 28, 2019Inventors: Giordano CAPONIGRO, Vesselina COOLE, Matthew John MEYER, Darrin STUART
-
Publication number: 20190345250Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: December 19, 2018Publication date: November 14, 2019Applicant: NOVARTIS AGInventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Matthew John Meyer, Konstanin Petropoulos, Engin Toksoz
-
Patent number: 10238748Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: August 7, 2015Date of Patent: March 26, 2019Assignee: Novartis AGInventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
-
Publication number: 20180193475Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: July 27, 2015Publication date: July 12, 2018Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 9982045Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: August 7, 2015Date of Patent: May 29, 2018Assignee: Novartis AGInventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
-
Publication number: 20170198040Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which selectively bind human CD32b. Also provided herein are compositions comprising the antibodies or antigen-binding fragments thereof, methods of using the antibodies or antigen-binding fragments thereof, and methods of making the antibodies or antigen-binding fragments thereof.Type: ApplicationFiled: December 16, 2016Publication date: July 13, 2017Applicant: Novartis AGInventors: Nicole BALKE, Thomas CALZASCIA, Stefan EWERT, Alan HARRIS, Heather Adkins HUET, Isabelle ISNARDI, Haihui LU, Matthew John MEYER, Nicholas WILSON, Fangmin WU
-
Publication number: 20170106095Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: October 11, 2016Publication date: April 20, 2017Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20170008964Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: July 7, 2016Publication date: January 12, 2017Applicant: Novartis AGInventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen HU, David Jenkins, Matthew John Meyer, Konstantin Petropoulos, Engin Toksoz
-
Patent number: 9498532Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: March 11, 2014Date of Patent: November 22, 2016Assignee: Novartis AGInventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20160046711Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: August 7, 2015Publication date: February 18, 2016Applicant: NOVARTIS AGInventors: Carl Uli BIALUCHA, Scott COLLINS, Clemens DÜRR, Tiancen HU, Mary Jo JANATPOUR, Matthew John MEYER
-
Publication number: 20140308201Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 16, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140301946Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer